Nervous System News and Research

Latest Nervous System News and Research

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Advanced microscope reveals process where mutations lead to autism and other diseases

Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.

22 Apr 2013

CI therapy appears to benefit children with cerebral palsy

Researchers at the University of Alabama at Birmingham (UAB) report that children with cerebral palsy who underwent Constraint Induced Movement therapy (CI therapy) saw a significant increase in grey matter volume in areas of the brain associated with movement.

22 Apr 2013

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

People lobbying for gun control may want to consider another culprit in the post-Newtown search for the answer to our unfathomable questions.

22 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

Researchers map use of alternative treatment among multiple sclerosis patients

A major Nordic research project involving researchers from the University of Copenhagen has, for the first time ever, mapped the use of alternative treatment among multiple sclerosis patients - knowledge which is important for patients with chronic disease and the way in which society meets them.

19 Apr 2013

Research shows infants experience automatic calming reaction when carried by their mothers

There is a very good reason mothers often carry their crying babies, pacing the floor, to help them calm down. New research published in the Cell Press journal Current Biology on April 18 shows that infants experience an automatic calming reaction upon being carried, whether they are mouse or human babies.

19 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Excess glutamate drives schizophrenia in high-risk individuals

An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center published in the current issue of Neuron.

19 Apr 2013

Study shows long-term exposure to fine particle matter air pollution is associated with atherosclerosis

The association between road traffic and heart disease has been suggested in several studies. In 2012 a large prospective cohort study from Denmark showed that traffic noise was significantly associated with risk of heart attack - for every 10 decibel increase in noise exposure (either at the time of the attack or over the five years preceding it) there was a 12% increased risk.

18 Apr 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

UTHealth neuroscientists demonstrate new strategy to overcome memory deficits

Neuroscientists at The University of Texas Health Science Center at Houston have taken a major step in their efforts to help people with memory loss tied to brain disorders such as Alzheimer's disease.

18 Apr 2013

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.

18 Apr 2013

Americans with brain diseases have more difficulty in finding a neurologist, new study reveals

Americans with brain diseases such as Alzheimer's disease, Parkinson's disease or multiple sclerosis who need to see a neurologist may face longer wait times or have more difficulty finding a neurologist, according to a new study published in the April 17, 2013, online issue of Neurology-, the medical journal of the American Academy of Neurology.

18 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

New paper discusses success of boot camp courses related to neurosurgery

In July 2010, the Society of Neurological Surgeons initiated nationwide boot camp courses designed to teach incoming postgraduate Year 1 trainees fundamental skills related to the field of neurosurgery.

17 Apr 2013

With Bio-patch sensor, health care can be moved into home, researcher says

The future of health care could be found in a tiny, paper-thin skin patch that collects vital information. The Bio-patch sensor developed by researchers at Stockholm's KTH Royal Institute of Technology is inexpensive, versatile and, best of all, comfortable to wear.

17 Apr 2013

Nervous System News and Research

Latest Nervous System News and Research

Animal models of Huntington's disease allow better insights into disease's genetics

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Advanced microscope reveals process where mutations lead to autism and other diseases

CI therapy appears to benefit children with cerebral palsy

Sleep related breathing disorders associated with cognitive and behavioral impairment in children

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Researchers map use of alternative treatment among multiple sclerosis patients

Research shows infants experience automatic calming reaction when carried by their mothers

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Excess glutamate drives schizophrenia in high-risk individuals

Study shows long-term exposure to fine particle matter air pollution is associated with atherosclerosis

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

UTHealth neuroscientists demonstrate new strategy to overcome memory deficits

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

Americans with brain diseases have more difficulty in finding a neurologist, new study reveals

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

New paper discusses success of boot camp courses related to neurosurgery

With Bio-patch sensor, health care can be moved into home, researcher says

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in